Switzerland
CIS Pharma is a biopharmaceutical company based in the Basel Area, Switzerland. Specializing in the development of next-gen immuno-conjugates, ADCs, and radioligand treatments, the company targets cancer patients with poor prognosis and a high spread of metastases. With assets including two targeting moieties against CD 171 and CD 276, as well as a polymer carrier technology, CIS Pharma aims to overcome current limitations in immuno-conjugates. Their technology stands out for its high-yield labeling of proteins, increased DAR, and precision in creating combination therapies.
Founded in 1952, CIS Pharma operates in the Biotechnology and Pharmaceutical industries, showcasing a long-standing commitment to innovation. While the latest investment details are not available, the company's focus on pioneering cancer treatments in Switzerland solidifies its position as an attractive prospect for potential venture capital involvement.
